Method of treating diseases using an il-17 receptor antibody formulation

A method of treating Sjögren's syndrome, dermatomyositis, or

• systemic lupus erythematosus in a human patient in need thereof, which method comprises administering to the patient an effective amount of a formulation comprising (i) 30 mM glutamic acid, (ii) a pH of 4.8±0.2, (iii) 3±0.2% proline (w/v), (iv) 0.01±0.002% (w/v) polysorbate 20, and (v) a human monoclonal antibody, or an antigen-binding fragment thereof, wherein the human monoclonal antibody comprises:
• (a) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
• 5, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
• 7, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
• 8, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
• 9, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
• 10, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
• 11;
• (b) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
• 3 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:
• 4;
• or
• (c) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
• 1 or SEQ ID NO:
• 12 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:
• 2;
• wherein the formulation comprises a dose of human monoclonal antibody of about 70 mg, about 140 mg, about 210, or about 280 mg, and whereby the human monoclonal antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to IL-17 receptor A, and the Sjögren's syndrome, dermatomyositis, or systemic lupus erythematosus is treated in the human patient.